Pharma Pulse Daily Digest

All News Deals Social Blogs Videos Podcasts Digests

PHARMA PULSE

Saturday, April 4, 2026

Market Intelligence for Pharma Professionals

🎯 Today's Pharma PulseUpdated 2h ago

Shionogi completes $2.5B acquisition of ALS drug Radicava

Shionogi has finalized a $2.5 billion purchase of global rights to the ALS therapy Radicava from Tanabe Pharma, adding a rare‑disease asset and a U.S. commercial platform that is expected to generate roughly $700 million in revenue starting fiscal 2026.

Also developing:

By the numbers: Lupin Limited acquires VISUfarma in undisclosed deal

⭐ Big Story of the Day

Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity

The FDA’s November 1, 2024 drug safety communication reports a preliminary review of suicidal thoughts and actions among patients using glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs). After analyzing adverse event reports, clinical trials and observational studies, regulators found no clear causal link, though the low event count prevents ruling out a modest risk. Ongoing meta‑analyses and Sentinel System data mining aim to provide a definitive safety assessment. Patients are advised not to stop therapy without medical guidance and to report any mood changes promptly.

Source: FDA

🚀 Top Pharma Headlines

FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (Fezolinetant) for Hot Flashes Due to Menopause

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Stop medicine if signs and symptoms of liver injury occur.

FDA

FDA Approves Extension of Eylea HD Dosing Intervals

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related macular degeneration, Regeneron Pharmaceuticals, Inc. announced. The approval, which extended the dosing intervals up to every 20 weeks, also includes an update to the Eylea HD (aflibercept 8 mg, Regeneron) label to include 2-year data from “the pivotal” PULSAR and PHOTON trials, according to a press release. “The potential for needing only two or three Eylea HD injections a year to manage certain retinal diseases is an exciting advance that could benefit

Healio – All News

Zanubrutinib Demonstrates Favorable Tolerability in R/R CLL/SLL

AJMC (The American Journal of Managed Care)

A Potential Universal Flu Shot? Intranasal EV Vaccine Protected Mice From H5N1, H7N9

A novel vaccine platform has been developed to induce broad, protective immunity against numerous influenza virus infections, showing promise as an effective mucosal vaccine strategy, according to a study published by researchers in the Institute for Biomedical Sciences at Georgia State University.

Medical Xpress

Molecular End Points Poised to Transform Myeloma Drug Approval: Nicholas Richardson, DO, MPH

AJMC (The American Journal of Managed Care)

💬 Top Pharma Social Posts

Thread by @sciencex.physorg

An intranasal vaccine using extracellular vesicles displaying inverted influenza hemagglutinins induced broad, cross-protective immunity in mice, offering a promising strategy for universal flu prevention at the mucosal level. vaccines

by Phys.org Threads•

Tweet by @Ramez

I mis-spoke here. This study showed 5-meo-DMT much more effective than psilocybin. This was specifically on treatment resistant depression. A 15 point MADRS reduction there is ~2x psilocybin and ~3x ketamine. 5-meo-DMT really is the most potent antidepressant known to science.

by Ramez Naam•

📈 Pharma Stock Movers

🟢 Top Weekly Gainers

BioNTech (BNTX)+6.18%

$91.18 | N/A Market Cap

Lilly (LLY)+5.30%

$935.58 | N/A Market Cap

Novo Nordisk (NVO)+5.27%

$36.98 | N/A Market Cap

🔴 Top Weekly Losers

Biogen (BIIB)-4.74%

$177.34 | N/A Market Cap

AbbVie (ABBV)-1.61%

$208.84 | $395.9B Market Cap

Amgen (AMGN)-1.11%

$347.94 | N/A Market Cap

PHARMA PULSE

Saturday, April 4, 2026

Market Intelligence for Pharma Professionals

🎯 Today's Pharma PulseUpdated 2h ago

Shionogi completes $2.5B acquisition of ALS drug Radicava

Shionogi has finalized a $2.5 billion purchase of global rights to the ALS therapy Radicava from Tanabe Pharma, adding a rare‑disease asset and a U.S. commercial platform that is expected to generate roughly $700 million in revenue starting fiscal 2026.

Also developing:

By the numbers: Lupin Limited acquires VISUfarma in undisclosed deal

⭐ Big Story of the Day

Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity

The FDA’s November 1, 2024 drug safety communication reports a preliminary review of suicidal thoughts and actions among patients using glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs). After analyzing adverse event reports, clinical trials and observational studies, regulators found no clear causal link, though the low event count prevents ruling out a modest risk. Ongoing meta‑analyses and Sentinel System data mining aim to provide a definitive safety assessment. Patients are advised not to stop therapy without medical guidance and to report any mood changes promptly.

Source: FDA

🚀 Top Pharma Headlines

FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (Fezolinetant) for Hot Flashes Due to Menopause

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Stop medicine if signs and symptoms of liver injury occur.

FDA

FDA Approves Extension of Eylea HD Dosing Intervals

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related macular degeneration, Regeneron Pharmaceuticals, Inc. announced. The approval, which extended the dosing intervals up to every 20 weeks, also includes an update to the Eylea HD (aflibercept 8 mg, Regeneron) label to include 2-year data from “the pivotal” PULSAR and PHOTON trials, according to a press release. “The potential for needing only two or three Eylea HD injections a year to manage certain retinal diseases is an exciting advance that could benefit

Healio – All News

Zanubrutinib Demonstrates Favorable Tolerability in R/R CLL/SLL

AJMC (The American Journal of Managed Care)

A Potential Universal Flu Shot? Intranasal EV Vaccine Protected Mice From H5N1, H7N9

A novel vaccine platform has been developed to induce broad, protective immunity against numerous influenza virus infections, showing promise as an effective mucosal vaccine strategy, according to a study published by researchers in the Institute for Biomedical Sciences at Georgia State University.

Medical Xpress

Molecular End Points Poised to Transform Myeloma Drug Approval: Nicholas Richardson, DO, MPH

AJMC (The American Journal of Managed Care)

💬 Top Pharma Social Posts

Thread by @sciencex.physorg

An intranasal vaccine using extracellular vesicles displaying inverted influenza hemagglutinins induced broad, cross-protective immunity in mice, offering a promising strategy for universal flu prevention at the mucosal level. vaccines

by Phys.org Threads•

Tweet by @Ramez

I mis-spoke here. This study showed 5-meo-DMT much more effective than psilocybin. This was specifically on treatment resistant depression. A 15 point MADRS reduction there is ~2x psilocybin and ~3x ketamine. 5-meo-DMT really is the most potent antidepressant known to science.

by Ramez Naam•